A novel ribozyme target site located in the HIV-1 nef open reading frame

Virology

Volumn 219, Issue 1, 1996, Pages 161-169

  Larsson, Sten ^a   Hotchkiss, Graham ^a   Su, Jn ^b   Kebede, Tegest ^b   Andandäng, Michael ^a   Nyholm, Tommy ^a   Johansson, Bo ^b   Sönnerborg, Anders ^b   Vahlne, Anders ^b   Britton, Sven ^b   Ährlund Richter, Lars ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

NEF PROTEIN; RIBOZYME;

ARTICLE; CONTROLLED STUDY; GENE THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; OPEN READING FRAME; PRIORITY JOURNAL;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0029937091     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1996.0233     Document Type: Article

References (38)

1. Ahmad, N., and Venkatesan, S. (1988). Nef protein of HIV-1 is a transcriptional repressor of HIV-1 LTR Science 241, 1481-1485. [Published erratum appears in Science, 1988, 242(4875), 242]
2. Aiken, C., and Trono, D. (1995). Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J. Virol. 69, 5048-5056.
3. Aiken, C., Konner, J., Landau, N. R., Lenburg, M. E., and Trono, D. (1994). Nef induces CD4 endocytosis: Requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell 76, 853-864.
4. Chen, C. J., Banerjea, A. C., Harmison, G. G., Haglund, K., and Schubert, M. (1992). Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication - potential effectiveness against most presently sequenced HIV-1 isolates. Nucleic Acids Res. 20, 4581-4589.
5. Crisell, P., Thompson, S., and James, W. (1993). Inhibition of HIV-1 replication by ribozymes that show poor activity in vitro. Nucleic Acids Res. 21, 5251-5255.
6. Dropuli'c, B., Lin, N. H., Martin, M. A, and Jeang, K. T. (1992). Functional characterization of a U5 ribozyme: Intracellular suppression of human immunodeficiency virus type 1 expression. J. Virol. 66, 1432-1441.
7. Efrat, S., Leiser, M., Wu, Y. J., Fusco-DeMane, D., Emran, O. A., Surana, M., Jetton, T. L., Magnuson, M. A., Weir, G., and Fleischer, N. (1994). Ribozyme-mediated attenuation of pancreatic beta-cell glucokinase expression in transgenic mice results in impaired glucose-induced insulin secretion. Proc. Natl. Acad. Sci. USA 91, 2051-2055.
8. Goodchild, J, and Kohli, V. (1991). Ribozymes that cleave an RNA sequence from human immunodeficiency virus: The effect of flanking sequence on rate. Arch. Biochem. Biophys. 284, 386-391.
9. Gura, T. (1995). Antisense has growing pains. Science 270, 575-577.
10. Heidenreich, Q., and Eckstein, F. (1992). Hammerhead ribozyme-mediated cleavage of the long terminal repeat RNA of human immunodeficiency virus type 1. J. Biol. Chem. 267, 1904-1909.
11. Homann, M., Tzortzakaki, S., Rittner, K., Sczakiel, G., and Tabler, M. (1993). Incorporation of the catalytic domain of a hammerhead ribozyme into antisense RNA enhances its inhibitory effect on the replication of human immunodeficiency virus type 1. Nucleic Acids Res. 21, 2809-2814.
12. Jeang, K. T., and Berkhout, B. (1992). Kinetics of HIV-1 long terminal repeat trans-activation: Use of intragenic ribozyme to assess rate-limiting steps. J. Biol. Chem. 267, 17891-17899.
13. Joseph, S., and Burke, J. M. (1993). Optimization of an anti-HIV hairpin ribozyme by in vitro selection. J. Biol. Chem. 268, 24515-24518.
14. Kerr, R. A. (1995). AIDS mood upbeat - for a change. Science 267, 960-961.
15. Kestler, H., III, Rngler, D. J., Mori, K., Panicali, D. L., Sehgal, P. K., Daniel, M. D., and Desrosiers, R. C. (1991). Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 65, 651-662.
16. Larson, G. P., Bertrand, E., and Rossi, J. J. (1993). Design and testing ribozymes as therapeutic agents. Methods 5, 19-27.
17. Larsson, S., Hotchkiss, G., Andang, M., Nyholm, T., Inzunza, J., Jansson, I., and Ahrlund-Richter, L. (1994). Reduced beta 2-microglobulin mRNA levels in transgenic mice expressing a designed hammerhead ribozyme. Nucleic Acids Res. 22, 2242-2248.
18. Lo, K. M., Biasolo, M. A., Dehni, G., Palu, G., and Haseltine, W. A. (1992). Inhibition of replication of HIV-1 by retroviral vectors expressing tat-antisense and anti-tat ribozyme RNA. Virology 190, 176-183.
19. Niederman, T. M., Thielan, B. J., and Ratner, L. (1989). Human immunodeficiency virus type 1 negative factor is a transcriptional silencer. Proc. Natl. Acad. Sci. USA 86, 1128-1132.
20. Rossi, J. J. (1995). Controlled, targeted, intracellular expression of ribozymes: Progress and problems. Trends Biotechnol. 13, 301-306.
21. Rossi, J. J., and Sarver, N. (1992). Catalytic antisense RNA (ribozymes): Their potential and use as anti-HIV-1 therapeutic agents. In "Innovations in Antiviral Development and the Detection of Virus Infection" (T. Block et al., Eds.), pp. 95-109. Plenum, New York.
22. Saksela, K., Cheng, G., and Baltimore, D. (1995). Proline-rich (PxxP) motifs in HIV-1 Nef bind to SH3 domains of a subset of src kinases and are required for the enhanced growth of Nef viruses but not for down-regulation of CD4. EMBO J. 14, 484-491.
23. Sarver, N., Cantin, E. M., Chang, P. S., Zaia, J A., Ladne, P. A., Stephens., D. A., and Rossi, J. J. (1990). Rbozymes as potential anti-HIV-1 therapeutic agents. Science 247, 1222-1225.
24. Schwartz, Q., Marechal, V., Danos, Q., and Heard, J. M. (1995). Human immunodeficiency virus type 1 Nef increases the efficiency of reverse transcription in the infected cell. J. Virol. 69, 4053-4059.
25. Sioud, M., and Drlica, K. (1991). Prevention of human immunodeficiency virus type 1 integrase expression in Escherichia coli by a ribozyme. Proc. Natl. Acad. Sci. USA 88, 7303-7307.
26. Sönnerborg, A., Abens, J., Johnsson, B., and Strannegård, O. (1990). Detection of human immunodeficiency virus-1 by polymerase chain reaction and virus cultivation. J. Med. Virol. 31, 234-240.
27. Subbramanian, R. A., and Cohen, E. A. (1994). Molecular biology of the human immunodeficiency virus accessory proteins. J. Virol. 68, 6831-6835.
28. Sullenger, B. A., and Cech,T. R. (1993). Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA. Science 262, 1566-1569.
29. Sullivan, S. M. (1994). Development of ribozymes for gene therapy. J. Invest. Dermatol. 103, 85S-89S.
30. Tabler, M., Homan, M., Tzortzakaki, S., and Sczakel, G. (1994). A three-nucleotide helix I is sufficient for full activity of a hammerhead ribozyme: Advantages of an asymmetric design. Nucleic Acids Res. 22(19), 3958-3965.
31. Vahlne, A., Nilheden, E., and Svennerholm, B. (1981). Multiplicity activation of herpes simplex virus in mouse neuroblastoma (C1300) cells. Arch. Viol. 70, 345-356.
32. Vaishnav, Y. N., and Wong-Staal, F. (1991). The biochemistry of AIDS. Annu. Rev. Biochem. 60, 577-630. [Review]
33. Ventura, M., Wang, P., Franck, N., and Saragosti, S. (1994). Ribozyme targeting of HIV-1 LTR Biochem. Biophys. Res. Commun. 203, 889-898.
34. Wagner, R. W. (1994). Gene inhibition using antisense oligodeoxynucleotides. Nature 372, 333-335.
35. Weerasinghe, M., Liem, S. E., Asad, S., Read, S. E., and Joshi, S. (1991). Resistance to human immunodeficiency virus type 1 (HIV-1) infection in human CD4+ lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme. J. Virol. 65, 5531-5534.
36. Yu, M., Ojwang, J., Yamada, Q., Hampel, A., Rapapport, J., Looney, D., and Wong-Staal, F. (1993). A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 90, 6340-6344.
37. Yu, M., Poeschla, E., and Wong-Staal, F. (1994). Progress towards gene therapy for HIV infection. Gene Ther. 1, 13-26.
38. Zhou, C., Bahner, I. C., Larson, G. P., Zaia, J. A., Rossi, J. J., and Kohn, E. B. (1994). Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes. Gene 149, 33-39.